Literature DB >> 1878894

Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

E C De Boer1, W H De Jong, A P Van Der Meijden, P A Steerenberg, J A Witjes, P D Vegt, F M Debruyne, E J Ruitenberg.   

Abstract

To study the mode of action of intravesical bacillus Calmette-Guérin (BCG) immunotherapy in the prevention and cure of superficial bladder cancer, flow-cytofluorometric analysis of the cellular immunological reaction in the urine of patients was performed. Fresh urine-derived leucocytes were obtained from eight patients before (t0) and 24 h (t24) and 48 h (t48) after repeated intravesical BCG instillations (at least 5 instillations). For two patients urine-derived leucocytes were investigated at the first BCG instillation. The number of leucocytes in the urine was markedly increased 24 h after repeated BCG instillations, indicating a local cellular immunological reaction induced by BCG. The mean number of cells per milliliter of urine at that time was 2.9 x 10(6) +/- 3.6 x 10(6) (n = 8). These leucocytes consisted mainly of granulocytes (75 +/- 11%, n = 8). In addition monocytes/macrophages (4 +/- 2%, n = 8) and T lymphocytes were present (1 +/- 1%, n = 5). The relative increase of monocytes/macrophages in the urine after BCG application tended to be higher compared to the other leucocyte subtypes. As T lymphocytes may play an important role in the BCG-mediated anti-tumour activity, subsets of lymphocytes were further characterized at t0, t24, and t48 after repeated BCG instillations. The lymphocyte population consisted mainly of T cells (86% CD3+, t0). Most of the T cells were CD4+ (helper/inducer) and were significantly decreased at 48 h (62 +/- 9% at t0 vs 49 +/- 6% at t48). Lymphocytes partly expressed HLA-DR antigens (44%, t0). The percentage of lymphocytes with interleukin-2 (IL-2) receptors (CD25+) was significantly increased at 24 h and 48 h, compared to pre-instillation values (19 +/- 11% and 10 +/- 4% vs 3 +/- 3% respectively). Natural killer cells (CD16+ and/or CD56+) and B cells (CD19+) were less numerous (10% and 19% at t0 respectively). After the first BCG instillation the increase in the number of leucocytes in urine seemed to be less compared to the numbers after repeated BCG instillations. Lymphocytes could not be detected in the urine collected before or after the first BCG instillation. In conclusion, we demonstrated the presence of considerable numbers of leucocytes in the urine 24 h after repeated BCG instillations, i.e. shortly after immunological activation. The antigen expression of the lymphocytes suggested that they may represent the lymphocytes in the bladder wall. Expression of HLA-DR and IL-2 receptors on lymphocytes indicated activation of T cells by the intravesical BCG treatment.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878894     DOI: 10.1007/bf01741603

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

Review 1.  Mechanism of cytotoxicity by natural killer (NK) cells.

Authors:  R B Herberman; C W Reynolds; J R Ortaldo
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

2.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

3.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

4.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro.

Authors:  V B Antony; S A Sahn; A C Antony; J E Repine
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Human phagocytic cell responses to Mycobacterium leprae and Mycobacterium bovis Bacillus Calmette-Guérin. An in vitro comparison of leprosy vaccine components.

Authors:  T J Holzer; L Kizlaitis; M Vachula; C W Weaver; B R Andersen
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

7.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989

8.  Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis.

Authors:  H D Adolphs; H W Schwabe; B Helpap; C Volz
Journal:  Urol Res       Date:  1984

9.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

10.  HLA-DR expression by high grade superficial bladder cancer treated with BCG.

Authors:  S Prescott; K James; A Busuttil; T B Hargreave; G D Chisholm; J F Smyth
Journal:  Br J Urol       Date:  1989-03
View more
  36 in total

1.  Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.

Authors:  Y Luo; X Chen; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 2.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

3.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

4.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 5.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

6.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

7.  Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

Authors:  T M de Reijke; P C Vos; E C de Boer; R F Bevers; W H de Muinck Keizer; K H Kurth; D H Schamhart
Journal:  Urol Res       Date:  1993

8.  Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin.

Authors:  J S Shin; J H Park; J D Kim; J M Lee; S J Kim
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

Review 10.  Role of neutrophils in BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; Michael A O'Donnell; Thomas S Griffith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.